


PHARMACEUTICAL 2018

Seres Therapeutics Inc. Rank 179 of 349











Seres Therapeutics Inc. Rank 179 of 349

The relative strengths and weaknesses of Seres Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Seres Therapeutics Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 51% points. The greatest weakness of Seres Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 87% points.

The company's Economic Capital Ratio, given in the ranking table, is -186%, being 92% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	155,078
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	31,625
Liabilities, Non-Current	1,129
Other Assets	1,513
Other Compr. Net Income	3.0
Other Expenses	0
Other Liabilities	96,069
Other Net Income	2,015
Property and Equipment	32,931
Research and Development	89,455
Revenues	32,100
Selling, General and Administrative Expense	34,040

Output Variable	Value in 1000 USD
Assets	189,522
Liabilities	128,823
Expenses	123,495
Stockholders Equity	60,699
Net Income	-89,380
Comprehensive Net Income	-89,378
Economic Capital Ratio	-186%

